A sialate cyclodextrin inclusion compound and its preparation method and use
By inserting the ester bond functional groups of N-acetylneurine ester molecules into the cylindrical cavity of cyclodextrin to form a sialate cyclodextrin inclusion, the low bioavailability of N-acetylneurine and ester bonds are solved. The problem of poor stability has improved stability and shelf life, and the production process has been simplified through one-pot technology.
Patent Information
- Application Number
- CN202310563926.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-07
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2044-04-07
AI Technical Summary
As a polar molecule, N-acetylneuramine is difficult to be inclusive by cyclodextrin, resulting in low bioavailability, and the ester bonds modified after esterification have poor chemical stability in normal temperature storage environment, affecting their shelf life.
The cyclodextrin molecular capsule technology is used to embed the ester bond functional groups in N-acetyl neuraminine ester molecules into the cylindrical cavity to form a single-molecular inclusion compound, and the same reaction system is carried out through one pot method. Sialate cyclodextrin inclusions are synthesized to simplify production processes and improve stability and bioavailability.
It improves the stability and bioavailability of sialate molecules, extends the shelf life, and achieves rapid absorption and effective delivery of drugs through the molecular capsule technology of cyclodextrin.
Smart Images

Figure CN118178673B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and in particular, relates to a sialate cyclodextrin inclusion compound and a preparation method and application thereof. Background Art
[0002] Sialic acid is a family of monosaccharides, usually located in the outermost carbohydrate part of the cell membrane and in key positions of secreted glycoconjugates (glycolipids, glycoproteins and lipopolysaccharides), and is an important material basis for the diversification of glycoconjugate structures and functions. Sialic acid compounds play an indispensable role in many important biological, physiological and pathological processes of living organisms, directly participate in the interaction between cells and cells, cells and microorganisms, cells and toxins, cells and antibodies, and play an extremely important role in anti-inflammation, anti-tumor, anti-virus, and promoting the development of the nervous system. There are many types of sialic acid, and more than 50 types are currently known. In mammals, the most common sialic acid derivative is N-acetylneuraminic acid (Neu5Ac).
[0003] N-acetylneuraminic acid is a polar molecule because it contains a carboxyl group and generates a negative charge in the body. The cell membrane is mainly composed of protein and phosphate molecules, both of which are non-polar molecules. According to the principle of like dissolves like, polar molecules are not easy to pass through the cell membrane, but they are highly water-soluble and will be quickly metabolized and excreted in the body. Therefore, N-acetylneuraminic acid as a drug or nutrient is not conducive to direct cell absorption and has a low bioavailability.
[0004] Cyclodextrin is a cyclic oligosaccharide compound composed of 6-12 glucose molecules linked by starch enzymatic hydrolysis and cyclization. Common cyclodextrins are α-cyclodextrin, β-cyclodextrin, and γ-cyclodextrin. β-cyclodextrin is currently the most widely used at home and abroad. Cyclodextrin, as the main body, can embed hydrophobic drug molecules or functional groups of suitable size and shape as guest molecules into its cylindrical cavity to form a single molecule inclusion complex, so it is also called "molecular microcapsule" or "ultramicrocapsule". Animal and human studies have shown that cyclodextrin has good biocompatibility, does not cause immune response, has low toxicity and can increase drug stability. With the development and use of cyclodextrin inclusion technology, almost every dosage form may be improved by cyclodextrin inclusion technology. Cyclodextrin inclusion complexes have been shown to improve the bioavailability of some routes of administration, such as ocular, topical, oral, nasal, pulmonary, gastrointestinal and rectal routes.
[0005] The advantages of cyclodextrin inclusion technology in pharmaceutics include the following aspects: improving drug stability, increasing drug solubility and dissolution, powdering and preventing liquid drugs from volatilizing, masking the bad smell of drugs and reducing irritation, adjusting the drug release rate to achieve rapid or sustained release of drugs, improving drug bioavailability, and serving as a carrier for protein drugs and targeted preparations.
[0006] Cyclodextrin inclusion complexes improve the bioavailability of drugs by increasing their solubility and dissolution rate. Cyclodextrin inclusion complexes form complexes with cell membrane components (such as cholesterol, phosphatidylcholine, and protein), thereby changing the lipid barrier and enhancing drug absorption. After some drugs are included in cyclodextrin, the oxidation, photolysis, and hydrolysis reactions of the drugs are significantly weakened, and the chemical stability is improved.
[0007] As a polar molecule, N-acetylneuraminic acid has many polar groups (hydroxyl and carboxyl), good hydrophilicity, and no hydrophobic groups, so it is not easy to be included by non-polar cyclodextrin. Therefore, it is technically difficult to use cyclodextrin to directly include N-acetylneuraminic acid to facilitate rapid and direct cell absorption.
[0008] Esterification of carboxyl groups is the most commonly used modification method in drug chemical structure modification, and is also a method for prodrug modification. The ester bond can lock the local molecular structure into a partially unfolded conformation, keeping water inaccessible to a large extent, which can reduce the polarity, dissociation degree or acidity and alkalinity of the drug, reduce the irritation of the drug, and change the pharmacokinetic properties of the drug. By esterifying the carboxyl group of N-acetylneuraminic acid, the polarity of the molecule can be reduced, which is conducive to the rapid absorption and utilization of N-acetylneuraminic acid by cells. However, the chemical stability of the ester bond is poor in room temperature storage environment and physiological environment, and it is easy to hydrolyze. Therefore, how to enhance the stability of N-acetylneuraminic acid ester molecules and effectively extend the shelf life is an important technical problem that needs to be solved in the application of N-acetylneuraminic acid esters formed by esterification modification of N-acetylneuraminic acid. Summary of the invention
[0009] In view of the above-mentioned deficiencies in the prior art, the present invention provides a sialate cyclodextrin inclusion compound and a preparation method and use thereof. The prepared sialate cyclodextrin inclusion compound has good water solubility and stability.
[0010] The present invention uses cyclodextrin molecular encapsulation technology to prepare N-acetylneuraminic acid ester molecule cyclodextrin inclusion complexes with cyclodextrin for the first time, embedding the hydrophobic ester bond functional groups in the N-acetylneuraminic acid ester molecules as guest molecules into the cylindrical cavity of cyclodextrin to form a single molecule inclusion complex, thereby achieving the multiple purposes of protecting the ester bond, improving the stability of N-acetylneuraminic acid ester molecules, extending the shelf life, and facilitating rapid cell uptake and absorption.
[0011] The present invention also proposes for the first time a one-pot technical solution for synthesizing sialic acid cyclodextrin inclusion compounds by esterification prodrug modification of carboxyl groups starting from N-acetylneuraminic acid, and then in the same reaction system. The light transmittance of the reaction solution can be detected by light illumination to automatically determine whether the reaction is completed, thereby greatly simplifying the production process of sialic acid cyclodextrin inclusion compounds, and the preparation steps are simple, which reduces the production cost, is safe and efficient, and the materials and solvents can be reused and recycled. The process is environmentally friendly, green and pollution-free, has no toxic substance residues, and is suitable for industrial production. The product is suitable for use as a food additive, feed additive, medicine, health care product, skin care product or cosmetic raw material, etc.
[0012] Technical Solution
[0013] To achieve the above object, the present invention provides the following technical solutions:
[0014] A sialate cyclodextrin inclusion compound, comprising: an N-acetylneuraminic acid derivative, and cyclodextrin or a derivative thereof;
[0015] Wherein, the molar ratio of the N-acetylneuraminic acid derivative to the cyclodextrin or its derivative is (1-5):(1-5),
[0016] Wherein, the molar ratio of the N-acetylneuraminic acid derivative to the cyclodextrin or its derivative is 1:1.
[0017] The N-acetylneuraminic acid derivative is an N-acetylneuraminic acid ester, and the N-acetylneuraminic acid ester includes N-acetylneuraminic acid methyl ester, N-acetylneuraminic acid ethyl ester, N-acetylneuraminic acid propyl ester, N-acetylneuraminic acid isopropyl ester, N-acetylneuraminic acid n-butyl ester, N-acetylneuraminic acid sec-butyl ester, N-acetylneuraminic acid tert-butyl ester, N-acetylneuraminic acid isobutyl ester, or its analogues.
[0018] The N-acetylneuraminic acid derivative is selected from any one of the compounds represented by formula (1) to formula (10), or an analog thereof,
[0019] (1) 2,4,7,8,9-penta-O-acetyl-N-acetylneuraminic acid
[0020] (2) 4,7,8,9-Tetra-O-acetyl-N-acetylneuraminic acid
[0021] (3) N-acetylneuraminic acid methyl ester
[0022] (4) N-acetylneuraminic acid ethyl ester
[0023] (5) 2,4,7,8,9-penta-O-acetyl-N-acetylneuraminic acid methyl ester
[0024] (6) 4,7,8,9-Tetra-O-acetyl-N-acetylneuraminic acid methyl ester
[0025] (7) N-acetylneuraminic acid deuterated methyl ester
[0026] (8) N-acetylneuraminic acid deuterated ethyl ester
[0027] (9) 2,4,7,8,9-penta-O-acetyl-N-acetylneuraminic acid deuterated methyl ester
[0028] (10) 4,7,8,9-Tetra-O-acetyl-N-acetylneuraminic acid deuterated methyl ester
[0029]
[0030] The cyclodextrin is selected from any one of β-cyclodextrin or its derivatives, γ-cyclodextrin or its derivatives, and α-cyclodextrin or its derivatives.
[0031] The cyclodextrin in the above-mentioned sialate cyclodextrin inclusion complex is hydroxypropyl-β-cyclodextrin, or hydroxypropyl-γ-cyclodextrin, or dimethyl-β-cyclodextrin, or dimethyl-γ-cyclodextrin, or sulfobutyl-β-cyclodextrin.
[0032] In the above-mentioned sialate cyclodextrin inclusion complex, the N-acetylneuraminic acid derivative is a compound represented by formula (3), formula (4), formula (7) or formula (8).
[0033] The method for preparing the sialate cyclodextrin inclusion compound as claimed in claim 1,
[0034] The following steps are involved:
[0035] (1) providing a supersaturated aqueous solution of cyclodextrin or its derivatives, and filtering to obtain a saturated aqueous solution of cyclodextrin or its derivatives;
[0036] (2) mixing a saturated aqueous solution of the cyclodextrin or its derivative with the N-acetylneuraminic acid derivative, wherein the N-acetylneuraminic acid derivative is preferably N-acetylneuraminic acid ester, and subjecting the mixture to ultrasonic treatment to obtain the sialic acid ester cyclodextrin inclusion complex, filtering the precipitated solid inclusion complex, washing away residual drugs on the solid surface, and freeze-drying the mixture to obtain a stable sialic acid ester cyclodextrin inclusion complex;
[0037] Wherein, the temperature of the ultrasonic treatment is 20-60°C;
[0038] The ultrasonic treatment time is 0.5-3h;
[0039] The frequency of the ultrasonic treatment is 30KHZ-100KHZ.
[0040] The method for preparing the sialate cyclodextrin inclusion compound as claimed in claim 1,
[0041] The method adopts a one-pot method to synthesize a sialic acid ester cyclodextrin inclusion complex, wherein a C1-C4 alcohol solution of the cyclodextrin or its derivative and N-acetylneuraminic acid are mixed, a catalytic amount of trifluoroacetic acid is added, and the mass ratio of the added trifluoroacetic acid to N-acetylneuraminic acid is 0.01‰-1.0%, wherein the selection of the C1-C4 alcohol depends on the target sialic acid ester, and the C1-C4 alcohol is one of methanol, ethanol, propanol, isopropanol, n-butanol, sec-butanol, tert-butanol, and isobutanol; the mixed solution of the C1-C4 alcohol solution of the cyclodextrin or its derivative and the N-acetylneuraminic acid is stirred for 2-7 days, and when the mixed solution is transformed from a white turbid liquid into a clear transparent solution, the C1-C4 alcohol solution is removed by rotary evaporation, reduced pressure distillation, or atomization drying to obtain a white and stable sialic acid ester cyclodextrin inclusion complex, and the C1-C4 alcohol solution is added with a molecular sieve for recovery and reuse;
[0042] Wherein, the reaction temperature is 20-60°C,
[0043] The reaction time is 2-7 days.
[0044] The sialate cyclodextrin inclusion compound as described above is used in the preparation of medicines and pharmaceutical compositions.
[0045] The dosage form of the medicine and pharmaceutical composition is a pharmaceutically acceptable dosage form.
[0046] The above-mentioned sialate cyclodextrin inclusion compound is used in the preparation of medicines and pharmaceutical compositions.
[0047] The dosage form of the drug and the drug composition is tablet, capsule, injection, granule, suppository, nasal spray, oral spray, atomized inhalation, powder, powder aerosol, ointment or gel;
[0048] The medicine and pharmaceutical composition are used to prepare the prevention and treatment of viral diseases, autoimmune diseases, nervous system diseases, inflammatory diseases, allergic diseases, tumors, acne, keloids, rhinitis, asthma, herpes zoster, prostatitis, new coronavirus infection and aging symptoms; wherein viral diseases include varicella-zoster virus infection, influenza virus infection, parainfluenza virus infection, coronavirus infection, respiratory syncytial virus infection, adenovirus infection, Newcastle disease virus infection, cytomegalovirus infection, rhinovirus infection, mumps virus infection, paramyxovirus infection and rotavirus infection.
[0049] The sialate cyclodextrin inclusion compound as described above is used in the preparation of food, health products and feed.
[0050] The sialate cyclodextrin inclusion compound as described above is used in the preparation of cosmetics and skin care products.
[0051] A method for preparing the sialate cyclodextrin inclusion complex as described above, wherein the methanol or alcohol solution of the cyclodextrin or its derivative and the N-acetylneuraminic acid are mixed and stirred for 2-7 days, and the specific steps of converting the solution from a white turbid liquid to a clear transparent solution are as follows:
[0052] S1. Mix the C1-C4 alcohol solution of cyclodextrin or its derivatives and the N-acetylneuraminic acid, stir for 2 hours using a stirring device, and then let it stand for 10 minutes for light detection. Use an array light to illuminate the solution from above and from the front, respectively, and collect the output intensity of the array light. The collection sequence of the array light from above is (k1, k2, k3, ..., k n ), where n is the number of array lights directly above, k i is the output intensity of the array lighting lamp directly above the i-th array lighting lamp, and the array lighting lamp in front (s1, s2, s3, ..., s n ), where s j is the output intensity of the j-th front array lighting;
[0053] S2. Set a light receiving plate at the bottom and back of the mixing container, and collect the receiving intensity of the bottom light receiving plate at the position corresponding to the array light directly above. The collected receiving intensity sequence is (K1, K2, K3, ..., K n ), where K i The receiving intensity of the bottom light receiving plate corresponding to the position of the array light directly above the i-th light is collected, and the receiving intensity of the back light receiving plate corresponding to the position of the array light on the front is collected. The collected receiving intensity sequence is (S1, S2, S3, ..., S n ), where S j The receiving intensity of the back light receiving panel at the position corresponding to the jth front array light is calculated, and the light transmittance at each position in the horizontal and vertical directions is calculated. The collected data is substituted into the calculation formulas of the horizontal light transmittance and the vertical light transmittance, and the calculation formula of the horizontal light transmittance is: The calculation formula for longitudinal transmittance is: The overall light transmittance is calculated from this, and the overall light transmittance calculation formula is: When the overall light transmittance meets the set qualified light transmittance range, execute step S3. If not, stir for 30 minutes and then perform light detection again.
[0054] S3, calculate the variance value of transmittance, This value is compared with the pre-set variance threshold. If the calculated variance value of the transmittance is greater than the pre-set variance threshold, it is necessary to stir for 30 minutes and then perform light detection again. If the calculated variance value of the transmittance is less than or equal to the pre-set variance threshold, it means that the stirring is completed.
[0055] In the infrared absorption spectrum, the stretching vibration region of the carbonyl group is 1900-1650cm -1 The absorption of carbonyl groups most often occurs in the region of 1755-1670 cm -1 . Since the electric dipole moment of the carbonyl group is large, the absorption is generally very strong and often becomes the first strong peak in the IR spectrum. Sialyl methyl ester contains a carbonyl group, while cyclodextrin does not. By detecting the infrared absorption spectrum of the carbonyl group of sialyl methyl ester-cyclodextrin inclusion complex, it can be determined whether the sialyl methyl ester-cyclodextrin inclusion complex is successfully prepared.
[0056] The infrared spectra of methyl sialate, hydroxypropyl-β-cyclodextrin and 2,6-dimethyl-β-cyclodextrin are shown as follows: Figure 8 , Fig. 9 , Fig.10 As shown, the infrared spectrum of the sialyl methyl ester hydroxypropyl-β-cyclodextrin inclusion complex of Example 1 is as follows Fig.11 As shown, the infrared spectrum of the sialyl methyl ester-2,6-dimethyl-β-cyclodextrin inclusion complex of Example 2 is as follows Fig.12 As shown, the infrared spectrum of the sialyl methyl ester hydroxypropyl-β-cyclodextrin inclusion complex of Example 3 is as follows Fig.13 As shown, the infrared spectrum of the sialyl methyl ester-2,6-dimethyl-β-cyclodextrin inclusion complex of Example 4 is as follows Fig.14 shown.
[0057] Sialic acid methyl ester at 1755~1670cm -1 There is an absorption peak due to carbonyl stretching vibration ( Figure 8 ); Hydroxypropyl-β-cyclodextrin and 2,6-dimethyl-β-cyclodextrin at 1755~1670cm -1 There is no absorption peak at Fig. 9 , Fig.10 ); The sialyl methyl ester hydroxypropyl-β-cyclodextrin inclusion complexes prepared in Example 1 and Example 3 were both at 1755-1670cm -1 There is an absorption peak due to carbonyl stretching vibration ( Fig.11 , Fig.13 ), indicating that the sialyl methyl ester hydroxypropyl-β-cyclodextrin inclusion complex was successfully prepared; the sialyl methyl ester-2,6-dimethyl-β-cyclodextrin inclusion complexes prepared in Example 2 and Example 4 were both at 1755-1670cm -1 There is an absorption peak due to carbonyl stretching vibration ( Fig.12 , Fig.14 ), indicating that sialyl methyl ester-2,6-dimethyl-β-cyclodextrin inclusion complex was successfully prepared.
[0058] The molecular docking (AD) method was used to demonstrate the host-guest molecular inclusion behavior at the molecular level. In the AutoDock 4.2 program, the semi-flexible docking method was used to dock the sialic acid methyl ester molecule into the cavity of hydroxypropyl-β-cyclodextrin. Hydroxypropyl-β-cyclodextrin was regarded as a rigid receptor molecule, and sialic acid methyl ester was allowed to be torsionally flexible. The Lamarckian genetic algorithm was used to perform 50 conformational searches. After cluster analysis, the docking conformation with the lowest binding energy was obtained, as shown in Figure 2. Fig.15 As shown in the figure. From the optimal conformation of docking, the methyl sialate molecule enters the cavity from the large end of hydroxypropyl-β-cyclodextrin, the methyl ester group is located inside the cavity of hydroxypropyl-β-cyclodextrin, and the glycerol part and N-acetyl group are located at the large end, finally forming a host-guest single-molecule inclusion complex in which hydroxypropyl-β-cyclodextrin is used as the host and the methyl ester functional group of methyl sialate is embedded in its cylindrical cavity as the guest molecule, namely, methyl sialate-hydroxypropyl-β-cyclodextrin inclusion complex, which is consistent with the nuclear magnetic resonance analysis ( Figure 3 , Figure 4 )’s results are consistent with those of
[0059] Beneficial Effects
[0060] Compared with the prior art, the present invention provides a sialic acid ester cyclodextrin inclusion compound, wherein the molar ratio of sialic acid ester to cyclodextrin is (1-5):(1-5), and preferably the molar ratio of sialic acid ester to cyclodextrin is 1:1. The present invention utilizes cyclodextrin molecular capsule technology to prepare the sialic acid ester cyclodextrin inclusion compound, and embeds the hydrophobic ester bond functional group in the sialic acid ester molecule as a guest molecule into the cylindrical cavity of the cyclodextrin to form a single molecule inclusion compound, thereby achieving the purpose of protecting the ester bond, improving the molecular stability of sialic acid esters, extending the shelf life, and improving the cell absorption performance of the drug.
[0061] The present invention creatively adopts a one-pot method to start with N-acetylneuraminic acid to perform esterification prodrug modification of the carboxyl group, and then synthesizes a sialate cyclodextrin inclusion compound in the same reaction system. A C1-C4 alcohol solution of cyclodextrin or its derivatives and N-acetylneuraminic acid are mixed, a catalytic amount of trifluoroacetic acid is added, the mass ratio of the added trifluoroacetic acid to N-acetylneuraminic acid is 0.01‰-1.0%, and stirring is performed for 2-7 days. In the one-pot reaction system, N-acetylneuraminic acid first reacts with C1-C4 alcohol to generate sialic acid ester, and the hydrophobic ester bond functional group in the sialic acid ester molecule is embedded in the cylindrical cavity of cyclodextrin as a guest molecule to form a sialate cyclodextrin inclusion compound. As the sialate cyclodextrin inclusion complex is formed, the sialate in the reaction system is continuously consumed, promoting the reaction of N-acetylneuraminic acid with C1-C4 alcohol to continue to form sialate, thereby forming an esterification prodrug modification of the carboxyl group starting from N-acetylneuraminic acid, and then synthesizing the sialate cyclodextrin inclusion complex in the same reaction system in a one-pot synthesis reaction, which greatly simplifies the production process of the sialate cyclodextrin inclusion complex and reduces the production cost.
[0062] The sialate cyclodextrin inclusion compound prepared by the invention has simple preparation steps, is safe and efficient, and the materials and solvents can be reused and recycled, is suitable for industrial production, is environmentally friendly, green and pollution-free, has no toxic substance residues, and is suitable for use as food additives, feed additives, medicines, health products, cosmetics and skin care product raw materials for humans or animals. Specifically, the sialate cyclodextrin inclusion complex does not affect the water solubility of sialate, but significantly increases the stability of the ester bond, which is beneficial for storage and prolongs the shelf life; under the action of cyclodextrin, the sialate cyclodextrin inclusion complex is beneficial for the drug delivery and cellular absorption of sialate; after the sialate cyclodextrin inclusion complex enters the cell, the cyclodextrin is degraded to release sialate, and the biological hydrolases such as carboxylesterase in the liver, intestine and other tissue cells will hydrolyze the ester bond of sialate, remove the ester group, and restore sialate to N-acetylneuraminic acid, which is incorporated into the biosynthetic pathway of sialic acid through the salvage synthesis pathway to quickly repair the damaged cell coat of sialic acid, thereby being able to more quickly and efficiently exert the nutritional, health, preventive, therapeutic, beauty and skin care effects of N-acetylneuraminic acid. BRIEF DESCRIPTION OF THE DRAWINGS
[0063] Figure 1 is the H NMR spectrum of methyl sialate;
[0064] Figure 2 is the carbon NMR spectrum of methyl sialate;
[0065] Figure 3 This is the hydrogen nuclear magnetic resonance spectrum of the methyl sialate-hydroxypropyl-β-cyclodextrin inclusion complex of Example 1;
[0066] Figure 4This is the carbon NMR spectrum of the sialyl methyl ester-hydroxypropyl-β-cyclodextrin inclusion complex of Example 1;
[0067] Figure 5 This is the hydrogen nuclear magnetic resonance spectrum of the methyl sialate-2,6-dimethyl-β-cyclodextrin inclusion complex of Example 2;
[0068] Figure 6 This is the carbon NMR spectrum of methyl sialate-2,6-dimethyl-β-cyclodextrin inclusion complex of Example 2;
[0069] Figure 7 This is a diagram of an oral spray product prepared from the sialic acid methyl ester-2,6-dimethyl-β-cyclodextrin inclusion complex obtained in Example 1;
[0070] Figure 8 is the infrared spectrum of methyl sialate;
[0071] Fig. 9 is the infrared spectrum of hydroxypropyl-β-cyclodextrin;
[0072] Fig.10 is the infrared spectrum of 2,6-dimethyl-β-cyclodextrin;
[0073] Fig.11 This is the infrared spectrum of the sialyl methyl ester hydroxypropyl-β-cyclodextrin inclusion complex of Example 1;
[0074] Fig.12 This is the infrared spectrum of methyl sialate-2,6-dimethyl-β-cyclodextrin inclusion complex of Example 2;
[0075] Fig.13 This is the infrared spectrum of the sialyl methyl ester hydroxypropyl-β-cyclodextrin inclusion complex of Example 3;
[0076] Fig.14 This is the infrared spectrum of the methyl sialate-2,6-dimethyl-β-cyclodextrin inclusion complex of Example 4;
[0077] Fig.15 This is the molecular docking conformation of sialyl methyl ester-hydroxypropyl-β-cyclodextrin inclusion complex. DETAILED DESCRIPTION
[0078] The technical solutions in the embodiments of the present invention are described in detail below, and the described embodiments are only some embodiments of the present invention. Based on the embodiments in the present invention, all other embodiments obtained by ordinary technicians in this field belong to the scope of protection of the present invention. The present invention is further described below in conjunction with specific embodiments.
[0079] It should be noted that if Figure 1 and Figure 2 As shown, the H NMR spectrum of methyl sialate:1 H NMR (400MHz, Deuterium Oxide) δ4.12–4.00 (m, 2H), 3.93 (t, J = 10.2 Hz, 1H), 3.83 (m, 4H), 3.77–3.71 (m, 1H), 3.63 (dd, J = 11.8, 6.3 Hz, 1H), 3.56 (d, J = 8.0 Hz, 1H), 2.32 (dd, J = 13.1, 4.9 Hz, 1H), 2.06 (s, 3H), 1.97–1.88 (m, 1H); C NMR spectrum of methyl sialate: 13 C NMR (101MHz, Deuterium Oxide) δ174.81, 171.38, 95.31, 70.32, 70.08, 68.17, 66.64, 63.12, 53.46, 52.03, 38.63, 22.04. At the same time, Figure 8 is the infrared spectrum of methyl sialate. Fig. 9 is the infrared spectrum of hydroxypropyl-β-cyclodextrin; Fig.10 This is the infrared spectrum of 2,6-dimethyl-β-cyclodextrin.
[0080] Example 1
[0081] Take methyl sialate (0.313g, 1.0mmol) and hydroxypropyl-β-cyclodextrin (1.541g, 1.0mmol) and dissolve them in 2g water. Ultrasonic reaction is carried out for 30-60min. The water temperature cannot exceed 35℃. After the reaction, freeze-drying and water removal are carried out to obtain 1.86g of solid compound. The yield is almost quantitative. The obtained solid compound is methyl sialate hydroxypropyl-β-cyclodextrin inclusion complex. The nuclear magnetic hydrogen spectrum and carbon spectrum are measured as follows Figure 3 , Figure 4 As shown, the infrared spectrum is as follows Fig.11 The nuclear magnetic resonance hydrogen spectrum of the sialyl methyl ester-hydroxypropyl-β-cyclodextrin inclusion complex of Example 1 is as follows: 1 H NMR (400MHz, Deuterium Oxide) δ5.25 (d, J = 11.6 Hz, 3H), 5.09 (q, J = 4.8, 4.4 Hz, 4H), 4.17-3.85 (m, 39H), 3.84 (s, 3H), 3.83-3.50 (m, 31H), 2.43-2.24 (m, 1H), 2.06 (s, 3H), 1.94 (d, J = 13.2 Hz, 1H), 1.16 (d, J = 6.6 Hz, 21H). The carbon nuclear magnetic resonance spectrum of the sialyl methyl ester-hydroxypropyl-β-cyclodextrin inclusion complex of Example 1: 13C NMR (101MHz, Deuterium Oxide)δ174.81,171.39,101.75,95.32,80.86,76.78,73.02,72.82,72.01,71.73,71.43,70.33,70.0 8,68.17,66.64,66.42,66.27,63.13,60.35,60.25,53.47,52.03,38.64,22.04,18.24,18.01,17.91.
[0082] Example 2
[0083] Take methyl sialate (0.313g, 1.0mmol) and 2,6-dimethyl-β-cyclodextrin (1.331g, 1.0mmol) and dissolve them in 2g water. Ultrasonic reaction is carried out for 30-60min. The water temperature should not exceed 35℃. After the reaction, freeze-drying and water removal are carried out to obtain 1.65g of solid compound. The yield is almost quantitative. The obtained solid compound is methyl sialate-2,6-dimethyl-β-cyclodextrin inclusion complex. The nuclear magnetic hydrogen spectrum and carbon spectrum are measured as follows Figure 5 , Figure 6 As shown, the infrared spectrum is as follows Fig.12 The nuclear magnetic resonance hydrogen spectrum of the sialyl methyl ester-2,6-dimethyl-β-cyclodextrin inclusion complex of Example 2 is as follows: 1 H NMR (400MHz, Deuterium Oxide) δ5.30–5.25 (m, 4H), 5.07 (s, 3H), 4.11–3.59 (m, 66H), 3.57 (s, 14H), 3.40 (s, 21H), 2.32 (dd, J=13.1, 4.8 Hz, 1H), 2.05 (s, 3H), 1.99–1.84 (m, 1H). The carbon nuclear magnetic resonance spectrum of the methyl sialate-2,6-dimethyl-β-cyclodextrin inclusion complex of Example 2: 13 C NMR (101MHz,Deuterium Oxide)δ174.81,171.39,102.04,99.56,95.32,81.02,72.61,71.74,70.54,69.6 1,69.44,68.18,66.10,63.13,60.28,59.65,59.08,58.37,48.25,38.63,22.04.
[0084] Example 3
[0085] Take sialic acid (0.299g, 1.0mmol), trifluoroacetic acid (0.114g, 0.001mol) and hydroxypropyl-β-cyclodextrin (1.541g, 1.0mmol) and dissolve them in 10ml of anhydrous methanol. Adjust the oil bath to 40℃ for reaction for 5 days. The reaction solution changes from white turbidity to colorless clear solution slowly after 3 days. During the reaction, the transmittance of the reaction solution is detected by light. After the transmittance reaches the set threshold and the reaction is completed, the methanol solution is removed by rotary evaporation to obtain 1.84g of solid compound with an almost quantitative yield. The methanol solvent after rotary evaporation is recovered and reused. The obtained solid compound is methyl sialate hydroxypropyl-β-cyclodextrin inclusion complex, and the infrared spectrum is as shown in the figure. Fig.13 shown.
[0086] Example 4
[0087] Take sialic acid (0.299g, 1.0mmol), trifluoroacetic acid (0.114g, 0.001mol) and 2,6-dimethyl-β-cyclodextrin (1.331g, 1.0mmol) and dissolve them in 12ml methanol. Adjust the oil bath to 37℃ for reaction for 5 days. The reaction solution changes from white turbidity to colorless clear solution after 3 days. During the reaction, the transmittance of the reaction solution is detected by light. After the transmittance reaches the set threshold and the reaction is completed, the methanol solution is removed by rotary evaporation to obtain 1.64g of solid compound with an almost quantitative yield. The methanol solvent after rotary evaporation is recovered and reused. The obtained solid compound is methyl sialate-2,6-dimethyl-β-cyclodextrin inclusion complex, and the infrared spectrum is as shown in the following figure. Fig.14 shown.
[0088] Example 5
[0089] The sialic acid methyl ester-hydroxypropyl-β-cyclodextrin inclusion compound obtained in Example 1 was used as a raw material to prepare a sialic acid methyl ester-hydroxypropyl-β-cyclodextrin inclusion compound capsule, the ingredients of which included:
[0090] (1) Sialyl methyl ester-hydroxypropyl-β-cyclodextrin inclusion complex, 180 mg;
[0091] (2) anhydrous lactose, 133 mg;
[0092] (3) microcrystalline cellulose, 132.5 mg;
[0093] (4) Magnesium stearate, 4.5 mg.
[0094] Sialyl acid methyl ester-hydroxypropyl-β-cyclodextrin inclusion complex capsules are used to treat COVID-19 infection, inflammation and allergic diseases.
[0095] Example 6
[0096] The sialyl methyl ester-hydroxypropyl-β-cyclodextrin inclusion compound capsule prepared in Example 5 was used to treat novel coronavirus infection:
[0097] Treatment case 1: Yan**, female, 32 years old, had a fever of 38.7℃, sore throat, and cough since December 15, 2022. She was diagnosed with COVID-19 by antigen test. On December 18, she still had a low fever of 37.5℃, accompanied by cough and sore throat. On December 18, 2022, she began to take the sialyl methyl ester-hydroxypropyl-β-cyclodextrin inclusion compound capsules obtained in Example 1 orally on an empty stomach, 4 capsules / time, 1 time / day. On December 19, 2022, the patient's body temperature returned to normal, her cough was mild, and her sore throat was significantly relieved. After taking it for 3 consecutive days, there was no pain in the throat and a mild cough.
[0098] Treatment case 2: Liu**, male, 48 years old. On December 7, 2022, his 17-year-old son had a high fever and cough. He was diagnosed with COVID-19 by antigen testing. On December 8, 2022, he took methyl sialate-hydroxypropyl-β-cyclodextrin inclusion compound capsules, 4 capsules / time, once a day. The fever subsided at night, there was no pain in the throat, and he had a slight cough. On December 9, 2022, Liu** himself had a fever and was diagnosed with COVID-19. On the same day, he took methyl sialate-hydroxypropyl-β-cyclodextrin inclusion compound capsules, 4 capsules / time, once a day. On December 10, 2022, the body temperature was 37.3℃, with a slight cough and slight pain in the throat. On December 9, 2022, his mother (82 years old) had a slight fever and took methyl sialate-hydroxypropyl-β-cyclodextrin inclusion compound capsules, 4 capsules / time, once a day. As of December 28, 2022, no confirmed symptoms of COVID-19 have appeared.
[0099] Treatment case 3: Chen**, female, 59 years old, a cancer survivor, developed fever of 38.5℃, sore throat, cough and other symptoms on December 22, 2022. She was diagnosed with COVID-19 by antigen test. She took sialyl methyl ester-hydroxypropyl-β-cyclodextrin inclusion compound capsules that night, 4 capsules / time, once a day. On December 23, 2022, her body temperature was 37℃, her throat was slightly sore, and she had a slight cough. She took it for 3 consecutive days, and her body temperature was normal, her throat was not sore, and she had a slight cough.
[0100] Treatment case 4: Li**, female, 72 years old, a patient with hypertension and diabetes, was diagnosed with COVID-19 by antigen test on December 25, 2022, and the nucleic acid test was negative one week later. As of January 30, 2023, the blood pressure has been 170, and medication is required to lower blood pressure, accompanied by nausea, cough, dizziness, fatigue, headache and other symptoms, and emotional instability. During this period, she went to the hospital for examination six times, and all indicators were normal. She was diagnosed with COVID-19 infection. At noon on January 30, 2023, she took methyl sialate-hydroxypropyl-β-cyclodextrin inclusion compound capsules, 4 capsules / time, 1 time / day. On January 31, 2023, the blood pressure was 150 / 85, and the original symptoms disappeared significantly. After taking it for 3 consecutive days, the original symptoms did not reappear.
[0101] Example 7
[0102] The sialyl methyl ester-hydroxypropyl-β-cyclodextrin inclusion compound capsule prepared in Example 5 is used to treat inflammatory and allergic diseases:
[0103] Treatment case: Feng**, female, 65 years old, suffered from severe urticaria and chronic allergies. Large patches of urticaria often occurred on the skin of the trunk, limbs and face. Oral loratadine had poor effect. Oral hormone drugs could control the symptoms. Due to long-term use of hormone drugs, the eyelids and cheekbones had light edema, local redness, and darker spots on the face. Orally take the sialyl methyl ester-hydroxypropyl-β-cyclodextrin inclusion compound capsule prepared in Example 5 on an empty stomach, 4 capsules / time, 1 time / day, for 7 consecutive days. Treatment effect: The larger spots on the skin of the trunk, limbs and face were significantly lighter, smaller or disappeared.
[0104] Example 8
[0105] The sialic acid methyl ester-2,6-dimethyl-β-cyclodextrin inclusion compound obtained in Example 2 was used as a raw material to prepare a physiological saline oral spray (such as Figure 7 shown), used to treat throat discomfort.
[0106] Example 9
[0107] A physiological saline oral spray containing 15% sialic acid methyl ester-2,6-dimethyl-β-cyclodextrin inclusion complex prepared in Example 8 is used to treat throat discomfort:
[0108] Treatment case 1: Jin**, male, 40 years old, 15 years of smoking experience, long-term pharyngitis, often accompanied by throat discomfort after getting up, yellow sputum after smoking too much. On January 16, 2023, he began to use a 15% saline oral spray containing methyl sialate-hydroxypropyl-β-cyclodextrin inclusion complex, and sprayed the mouth when he felt uncomfortable. After each spray, he could clearly feel the phlegm and other foreign bodies in his throat sink, and the bad breath caused by pharyngitis also disappeared significantly.
[0109] Treatment case 2: Jin**, male, 67 years old, 30 years of smoking, severe pharyngitis patient, phlegm in the throat after getting up at night, need to wash the throat to spit out. On January 20, 2023, he started using 15% sialyl methyl ester-hydroxypropyl-β-cyclodextrin inclusion complex of normal saline oral spray, and used it for 15 consecutive days. The pharyngitis was significantly improved, and there was no phlegm when getting up at night.
[0110] The above is a schematic description of the present invention and its implementation methods, which is not restrictive and only shows one of the implementation methods of the present invention. The actual structure and application are not limited thereto. Therefore, if a person skilled in the art is inspired by it and, without departing from the purpose of the invention, designs a structure and an implementation method similar to the technical solution without creativity, they shall all fall within the protection scope of the present invention.
Claims
1. A sialate cyclodextrin inclusion compound, characterized in that: include: N-acetylneuraminic acid derivatives and cyclodextrins; Wherein, the molar ratio of the N-acetylneuraminic acid derivative to the cyclodextrin is (1-5):(1-5), The N-acetylneuraminic acid derivative is selected from any one of the compounds represented by formula (3) to formula (10), (3) N-acetylneuraminic acid methyl ester (4) N-acetylneuraminic acid ethyl ester (5) 2,4,7,8,9-penta-O-acetyl-N-acetylneuraminic acid methyl ester (6) 4,7,8,9-Tetra-O-acetyl-N-acetylneuraminic acid methyl ester (7) N-acetylneuraminic acid deuterated methyl ester (8) N-acetylneuraminic acid deuterated ethyl ester (9) 2,4,7,8,9-penta-O-acetyl-N-acetylneuraminic acid deuterated methyl ester (10) 4,7,8,9-Tetra-O-acetyl-N-acetylneuraminic acid deuterated methyl ester The N-acetylneuraminic acid derivative is also selected from N-acetylneuraminic acid propyl ester, N-acetylneuraminic acid isopropyl ester, N-acetylneuraminic acid n-butyl ester, N-acetylneuraminic acid sec-butyl ester, N-acetylneuraminic acid tert-butyl ester or N-acetylneuraminic acid isobutyl ester; The cyclodextrin is selected from any one of β-cyclodextrin, γ-cyclodextrin and α-cyclodextrin.
2. The sialate cyclodextrin inclusion compound according to claim 1, characterized in that: The cyclodextrin is hydroxypropyl-β-cyclodextrin, or hydroxypropyl-γ-cyclodextrin, or dimethyl-β-cyclodextrin, or dimethyl-γ-cyclodextrin, or sulfobutyl-β-cyclodextrin.
3. The sialate cyclodextrin inclusion compound according to claim 1, characterized in that: The N-acetylneuraminic acid derivative is a compound represented by formula (3), formula (4), formula (7) or formula (8).
4. The method for preparing a sialate cyclodextrin inclusion compound according to any one of claims 1 to 3, characterized in that: The following steps are involved: (1) providing a supersaturated aqueous solution of cyclodextrin, and filtering to obtain a saturated aqueous solution of cyclodextrin; (2) mixing the saturated aqueous solution of the cyclodextrin and the N-acetylneuraminic acid derivative, and subjecting the mixture to ultrasonic treatment to obtain the sialate cyclodextrin inclusion complex, filtering the precipitated solid inclusion complex, washing away the residual drug on the solid surface, and freeze-drying the mixture to obtain a stable sialate cyclodextrin inclusion complex; Wherein, the temperature of the ultrasonic treatment is 20-60°C; The ultrasonic treatment time is 0.5-3h; The frequency of the ultrasonic treatment is 30KHZ-100KHZ.
5. A method for preparing a sialate cyclodextrin inclusion compound according to any one of claims 1 to 3, characterized in that: The method adopts a one-pot method to synthesize a sialic acid ester cyclodextrin inclusion compound. A C1-C4 alcohol solution of cyclodextrin and N-acetylneuraminic acid are mixed, and a catalytic amount of trifluoroacetic acid is added. The mass ratio of the added trifluoroacetic acid to the N-acetylneuraminic acid is 0.01‰-1.0%, wherein the selection of the C1-C4 alcohol depends on the target sialic acid ester, and the C1-C4 alcohol is one of methanol, ethanol, propanol, isopropanol, n-butanol, sec-butanol, tert-butanol, and isobutanol. The mixed solution of the C1-C4 alcohol solution of cyclodextrin and the N-acetylneuraminic acid is stirred for 2-7 days, and when the mixed solution is transformed from a white turbid liquid into a clear transparent solution, the C1-C4 alcohol solution is removed by rotary evaporation, reduced pressure distillation, or atomization drying to obtain a white and stable sialic acid ester cyclodextrin inclusion compound, and the C1-C4 alcohol solution is added with a molecular sieve for recovery and reuse. The reaction temperature is 20-60°C and the reaction time is 2-7 days.
6. The use of the sialate cyclodextrin inclusion compound according to claim 1, characterized in that: The sialate cyclodextrin inclusion compound is used in the preparation of medicines and pharmaceutical compositions; The dosage form of the drug and pharmaceutical composition is a pharmaceutically acceptable dosage form. The dosage form of the drug and the drug composition is tablet, capsule, injection, granule, suppository, nasal spray, oral spray, atomized inhalation, powder, powder aerosol, ointment or gel; The medicine and the pharmaceutical composition are used for preparing the prevention and treatment of viral diseases, autoimmune diseases, inflammatory diseases and allergic diseases.
7. The use of the sialate cyclodextrin inclusion compound according to claim 6, characterized in that: The inflammatory diseases include rhinitis, asthma, and prostatitis; The viral diseases include herpes zoster, varicella-zoster virus infection, influenza virus infection, parainfluenza virus infection, coronavirus infection, respiratory syncytial virus infection, adenovirus infection, Newcastle disease virus infection, cytomegalovirus infection, rhinovirus infection, mumps virus infection, paramyxovirus infection and rotavirus infection; The coronavirus infection includes the new coronavirus infection.
8. The use of the sialate cyclodextrin inclusion compound according to claim 6, characterized in that: The medicine and the medicine composition are used for preparing the medicine for preventing and treating acne and keloid.
9. Use of the sialate cyclodextrin inclusion compound as claimed in claim 1 in the preparation of food, health products and feed.
10. Use of the sialate cyclodextrin inclusion compound as claimed in claim 1 in the preparation of cosmetics and skin care products.
11. A method for preparing the sialate cyclodextrin inclusion compound as claimed in claim 5, characterized in that: The specific steps of mixing the C1-C4 alcohol solution of cyclodextrin and the N-acetylneuraminic acid and stirring for 2-7 days to transform the mixed solution from a white turbid solution into a clear transparent solution are as follows: S1. Mix the C1-C4 alcohol solution of cyclodextrin and the N-acetylneuraminic acid, stir for 2 hours using a stirring device, and then let it stand for 10 minutes for light detection. Use an array light to illuminate the solution from above and from the front, respectively, and collect the output intensity of the array light. The collection sequence of the array light from above is (k1, k2, k3, ..., k n ), where n is the number of array lights directly above, k i is the output intensity of the array lighting lamp directly above the i-th array lighting lamp, and the array lighting lamp in front (s1, s2, s3, ..., s n ), where s j is the output intensity of the j-th front array lighting; S2. Set a light receiving plate at the bottom and back of the mixing container, and collect the receiving intensity of the bottom light receiving plate at the position corresponding to the array light directly above. The collected receiving intensity sequence is (K1, K2, K3, ..., K n ), where K i The receiving intensity of the bottom light receiving plate corresponding to the position of the array light directly above the i-th light is collected, and the receiving intensity of the back light receiving plate corresponding to the position of the array light on the front is collected. The collected receiving intensity sequence is (S1, S2, S3, ..., S n ), where S j The receiving intensity of the back light receiving panel at the position corresponding to the jth front array light is calculated, and the light transmittance at each position in the horizontal and vertical directions is calculated. The collected data is substituted into the calculation formulas of the horizontal light transmittance and the vertical light transmittance, and the calculation formula of the horizontal light transmittance is: The calculation formula for longitudinal transmittance is: The overall light transmittance is calculated from this, and the overall light transmittance calculation formula is: When the overall light transmittance meets the set qualified light transmittance range, execute step S3. If not, stir for 30 minutes and then perform light detection again. S3, calculate the variance value of transmittance, This value is compared with the pre-set variance threshold. If the calculated variance value of the transmittance is greater than the pre-set variance threshold, it is necessary to stir for 30 minutes and then perform light detection again. If the calculated variance value of the transmittance is less than or equal to the pre-set variance threshold, it means that the stirring is completed.
